Clostridium septicum alpha toxin polyclonal antibody and application thereof in preparation of colloidal gold test strip for detecting fast sheep plague

By developing Clostridium α toxin polyclonal antibody and preparing colloidal gold test strips, the problem of difficulty in diagnosis of sheep fast epidemic disease is solved, rapid and accurate detection is achieved, and reliable detection methods are provided for sheep fast epidemic.

CN118894932AInactive Publication Date: 2024-11-05QINGHAI UNIVERSITY

Patent Information

Application Number
CN202411302977.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-11-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The diagnosis of sheep fast blight is difficult and harmful. The existing technology is difficult to detect Clostridium spoilage quickly and accurately, affecting the health and production of sheep.

Method used

Develop a polyclonal antibody of Clostridium spoilage α toxin, and use this antibody to prepare colloidal gold test strips, and achieve rapid and accurate qualitative detection through colloidal gold immunochromatography technology.

Benefits of technology

It has achieved rapid and accurate detection of sheep fast epidemics, with reliable test results and good sensitivity, and can still respond when the sample is diluted 40 times, providing technical support for pathogen diagnosis and vaccine development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894932A_ABST
    Figure CN118894932A_ABST
Patent Text Reader

Abstract

The invention provides a clostridium septicum alpha toxin polyclonal antibody and application thereof in preparation of a colloidal gold test strip for detecting fast sheep plague, and relates to the technical field of pathogen detection. The clostridium septicum alpha toxin polyclonal antibody is prepared by immunizing a test animal with a clostridium septicum alpha toxin antigen, and the amino acid sequence of the clostridium septicum alpha toxin antigen is as shown in SEQ ID NO. 1. The polyclonal antibody disclosed by the invention is purified and then used for establishing a colloidal gold test strip for the fast sheep plague, and the test strip can specifically react with a clostridium septicum serum sample; a clostridium septicum serum sample still reacts after being diluted by 40 times, so that the test strip is good in sensitivity, and a technical support is provided for clinical diagnosis of the clostridium septicum disease of livestock.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pathogen detection, and specifically relates to a polyclonal antibody of alpha toxin of Clostridium putrefaciens and application thereof in preparing a colloidal gold test strip for detecting sheep rapid disease. Background Art

[0002] Sheep blight is an acute infectious disease caused by infection with Clostridium putrefaciens, which mainly occurs in sheep. Sheep of different ages are highly susceptible to sheep blight. There are basically no clinical symptoms in the early stage after the onset of the disease. They suddenly fall to the ground and die. The onset process is relatively short, and the mortality rate caused is relatively high. Sick sheep with a relatively long onset time often show reluctance to walk, movement disorders, abdominal pain, diarrhea, molar convulsions, and finally weakness and coma, bloody foam in the mouth, and an extremely short course of disease. The disease is mainly infected through the digestive tract, and is characterized by hemorrhagic inflammatory lesions of the true stomach mucosa. Sheep blight has a serious impact on the healthy growth of the flock. Therefore, the diagnosis and prevention of sheep blight must be highly valued.

[0003] Clostridium putrefaciens is a Gram-positive anaerobic bacterium, classified as Clostridium. The bacterium can produce spores both in vivo and in vitro, does not form a capsule, and can produce a variety of exotoxins. Clostridium putrefaciens can secrete 4 toxins (α, β, γ, δ), the most important lethal virulence factor is Clostridium putrefaciens α toxin, which has multiple biological activities such as hemolysis, lethality and necrosis. Clostridium putrefaciens is widely present in the breeding environment, mainly in feces and soil, especially in some humid places where the number will increase significantly. It can stay in the polluted environment for a relatively long time, and mainly exists in the form of spores. Because this type of pathogen is widely distributed, it is very easy to contaminate the sheep feed and drinking water. If the sheep eats contaminated feed or drinks drinking water contaminated by the pathogen, Clostridium putrefaciens will infect the sheep through the digestive tract, posing a serious threat to the healthy growth of the sheep.

[0004] Because the course of sheep rapid blight is usually short and the harm is great, it is often difficult to diagnose it before the sheep dies. On the one hand, it needs to be combined with epidemiological investigation, and on the other hand, it needs to be combined with pathological autopsy changes. Therefore, the detection of Clostridium putrefaciens of sheep rapid blight is carried out in order to provide technical support for the clinical diagnosis of Clostridium putrefaciens disease in livestock. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide a polyclonal antibody to alpha toxin of Clostridium putrefaciens, which is used to establish a colloidal gold test strip for sheep rapid disease, thereby achieving the purpose of rapid and accurate qualitative detection of pathogens, and the detection results are accurate and reliable.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a polyclonal antibody against alpha toxin of Clostridium putrefaciens. The polyclonal antibody against alpha toxin of Clostridium putrefaciens is prepared by immunizing test animals with alpha toxin antigen of Clostridium putrefaciens. The amino acid sequence of the alpha toxin antigen of Clostridium putrefaciens is shown in SEQ ID NO.1.

[0008] Preferably, the method for preparing the Clostridium putrefaciens alpha toxin antigen comprises the following steps:

[0009] The whole genome of Clostridium putrefaciens was extracted, and the alpha toxin gene of Clostridium putrefaciens was amplified using the alpha toxin gene primers of Clostridium putrefaciens;

[0010] Connecting the Clostridium putrefaciens alpha toxin gene to a vector to obtain a recombinant vector;

[0011] The recombinant protein of alpha toxin of Clostridium putrefaciens is obtained by in vitro recombinant expression and purification, and the recombinant protein of alpha toxin of Clostridium putrefaciens is used as the alpha toxin antigen of Clostridium putrefaciens.

[0012] Preferably, the primers include an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is shown as SEQ ID NO.2; the nucleotide sequence of the downstream primer is shown as SEQ ID NO.3.

[0013] Preferably, the vector is pET-30a.

[0014] The present invention provides a method for preparing the polyclonal antibody against alpha toxin of Clostridium putrefaciens, comprising the following steps:

[0015] The purified recombinant protein of alpha toxin of Clostridium putrefaciens was used as an antigen to immunize mice subcutaneously at multiple points on the back; a booster immunization was performed two weeks later, and a second booster immunization was performed in the fourth week;

[0016] After the second booster immunization, blood was collected to determine the antibody titer, mouse serum was collected, and protein A was used to purify the mouse polyclonal antibody against the alpha toxin protein of Clostridium putrefaciens.

[0017] Preferably, the immunization dose is 80-120 μg / mouse.

[0018] The invention provides an application of the polyclonal antibody of Clostridium putrefaciens alpha toxin in preparing a test strip for detecting sheep rapid disease.

[0019] The invention provides a colloidal gold test strip for detecting sheep rapid disease. The test strip comprises a PVC plate, on which a sample pad, a gold label binding pad, a chromatographic membrane and a water absorbent pad are overlapped in sequence, the gold label binding pad is coated with the polyclonal antibody of Clostridium putrefaciens alpha toxin marked by colloidal gold particles, or the polyclonal antibody of Clostridium putrefaciens alpha toxin obtained by the preparation method and marked by colloidal gold particles; a detection line and a quality inspection line are sequentially arranged on the chromatographic membrane, the detection line is coated with the polyclonal antibody of Clostridium putrefaciens alpha toxin or the polyclonal antibody of Clostridium putrefaciens alpha toxin obtained by the preparation method, and the quality inspection line is coated with sheep anti-mouse IgG antibody.

[0020] Preferably, the sheep plague is caused by Clostridium putrefaciens.

[0021] Preferably, the concentration of the Clostridium putrefaciens alpha toxin polyclonal antibody is 0.5-3.0 mg / mL; the concentration of the goat anti-mouse IgG antibody is 1.0-4.0 mg / mL.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention constructs a prokaryotic expression plasmid of Clostridium putrefaciens alpha toxin, induces the expression of a target protein in large quantities under optimal induction conditions, and prepares a polyclonal antibody against Clostridium putrefaciens alpha toxin, and finally preliminarily establishes a colloidal gold test strip for sheep rapid disease, which can specifically react with a serum sample of Clostridium putrefaciens; the test strip still reacts when the serum sample of Clostridium putrefaciens is diluted 40 times, indicating that the test strip has good sensitivity. The present invention utilizes colloidal gold immunochromatography technology, combines the principles of chromatography and immune response, and achieves the purpose of rapid and accurate qualitative detection of pathogens. The test results are accurate and reliable, laying a foundation for the research and development of Clostridium putrefaciens disease vaccines and related drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 It is a schematic structural diagram of the colloidal gold test strip of the present invention;

[0025] Figure 2 The results of the whole genome extraction of Clostridium putrefaciens;

[0026] Figure 3 This is the result of PCR amplification of the alpha toxin gene of Clostridium putrefaciens;

[0027] Figure 4 It is the gene fragment of Clostridium putrefaciens alpha toxin produced after double enzyme digestion;

[0028] Figure 5 The results of obtaining a single band of Clostridium putrefaciens α-toxin protein after purification; A is the result of induced expression of α-toxin protein, and B is the result of purification of α-toxin protein;

[0029] Figure 6The results show that the mouse polyclonal antibody against the alpha toxin protein of Clostridium putrefaciens can specifically bind to the antigen;

[0030] Figure 7 It is the specific detection result of the colloidal gold test strip of the present invention;

[0031] Figure 8 The sensitivity test result of the colloidal gold test strip of the present invention is shown in FIG.

[0032] Fig. 9 The comparison results of the colloidal gold test strip of the present invention and the ELISA test on clinical samples;

[0033] Fig.10 It is a schematic diagram of some results of using the colloidal gold test strip of the present invention for clinical sample testing. DETAILED DESCRIPTION

[0034] The present invention provides a polyclonal antibody against alpha toxin of Clostridium putrefaciens. The polyclonal antibody against alpha toxin of Clostridium putrefaciens is prepared by immunizing test animals with alpha toxin antigen of Clostridium putrefaciens. The amino acid sequence of the alpha toxin antigen of Clostridium putrefaciens is

[0035] MSKKSFAKKVICTSMIAIQCAAVVPHVQAYALTNLEEGGYANHNNASSIKIFG

[0036] YEDNEDLKAKIIQDPEFIRNWANVAHSLGFGWCGGTANPNVGQGFEFKREVG

[0037] AGGKVSYLLSARYNPNDPYASGYRAKDRLSMKISNVRFVIDNDSIKLGTPKV

[0038] KKLAPLNSASFDLINESKTESKLSKTFNYTTSKTVSKTDNFKFGEKIGVKTSFK

[0039] VGLEAIADSKVETSFEFNAEQGWSNTNSTTETKQESTTYTATVSPQTKKRLFL

[0040] DVLGSQIDIPYEGKIYMEYDIELMGFLRYTGNAREDHTEDRPTVKLKFGKNG

[0041] MSAEEHLKDLYSHKNINGYSEWDWKWVDEKFGYLFKNSYDALTSRKLGGII

[0042] KGSFTNINGTKIVIREGKEIPLPDKRRGKRSVDSLDARLQNEGIRIENIETQDVPGFRLNSITYNDKKIDIN (SEQ ID NO. 1).

[0043] In the present invention, the method for preparing the Clostridium putrefaciens alpha toxin antigen comprises the following steps:

[0044] The whole genome of Clostridium putrefaciens was extracted, and the alpha toxin gene of Clostridium putrefaciens was amplified using the alpha toxin gene primers of Clostridium putrefaciens;

[0045] Connecting the Clostridium putrefaciens alpha toxin gene to a vector to obtain a recombinant vector;

[0046] The recombinant protein of alpha toxin of Clostridium putrefaciens is obtained by in vitro recombinant expression and purification, and the recombinant protein of alpha toxin of Clostridium putrefaciens is used as the alpha toxin antigen of Clostridium putrefaciens.

[0047] In the present invention, the method for extracting the whole genome of Clostridium putrefaciens can be extracted by referring to the instructions of the whole genome extraction kit. In the present invention, the whole genome extraction kit can be purchased from conventional commercial products. In the present invention, the whole genome extraction kit of Clostridium putrefaciens is preferably 2×Pro Taq HS Probe Premix, purchased from Bao Bioengineering Co., Ltd.; protein markers are purchased from Sevier Company; and primers are synthesized from Qingke Biotechnology Company.

[0048] In the present invention, the primers include an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is 5'-CCGGAATTCATGTCAAAAAAATCTTTTGCTAAAA-3' (SEQ ID NO.2); the nucleotide sequence of the downstream primer is CCGCTCGAGATTAATATCAATTTTTTTAT CATTG (SEQ ID NO.3). In the present invention, the primers are synthesized in Qingke Biotechnology Company.

[0049] In a specific embodiment of the present invention, the amplification reaction system of the alpha toxin gene of Clostridium putrefaciens is preferably: the total volume of the PCR reaction system is 50 μL, including 2×Pro Taq HS Probe Premix 25 μL, 2 μL of upstream and downstream primers, 2 μL of template, and RNA-free water is supplemented to 50 μL. In a specific embodiment of the present invention, the amplification procedure of the alpha toxin gene of Clostridium putrefaciens is preferably: 98°C, 2 min; 98°C, 10 s, 55°C, 5 s, 72°C, 10 s, 35 cycles; 72°C, 10 min.

[0050] In the present invention, the PCR amplification product of the alpha toxin gene of Clostridium putrefaciens is 1323 bp in size, and the nucleotide sequence of the alpha toxin gene of Clostridium putrefaciens is

[0051]

[0052] In the present invention, the vector is preferably pET-30a. The above-mentioned Clostridium putrefaciens alpha toxin gene is connected to the pET-30a expression vector to obtain the recombinant vector pET-30a-α-1323. In the present invention, the restriction endonucleases used in the construction of the recombinant vector pET-30a-α-1323 are preferably EcoR I and Xho I.

[0053] In the present invention, the in vitro recombinant expression method preferably includes the following steps: transferring the recombinant vector into BL21 expression competent cells for expression; small-scale induction found that the expression amount of Clostridium putrefaciens α-toxin recombinant protein can be the highest at 37°C and 180rpm / min, and large-scale expression can be performed under this condition. The specific process is preferably as follows: after the recombinant bacterial solution is revived overnight, it is added to 200ml LB medium at a ratio of 1:100 and shaken to the logarithmic phase (OD 600 =0.6-0.8), IPTG was added at a final concentration of 1 mM for overnight induction, and the mixture was centrifuged at 8000 rpm for 20 min, and the supernatant was discarded. The bacterial pellet was resuspended in about 20 ml of PBS, and the cell was disrupted by ultrasonication for 40 min, and then centrifuged at 8000 rpm for 20 min, and the supernatant and pellet were collected and identified by SDS-PAGE electrophoresis.

[0054] The present invention provides a method for preparing the polyclonal antibody against alpha toxin of Clostridium putrefaciens, comprising the following steps:

[0055] The purified recombinant protein of alpha toxin of Clostridium putrefaciens was used as an antigen to immunize mice subcutaneously at multiple points on the back; a booster immunization was performed two weeks later, and a second booster immunization was performed in the fourth week;

[0056] After the second booster immunization, blood was collected to determine the antibody titer, mouse serum was collected, and protein A was used to purify the mouse polyclonal antibody against the alpha toxin protein of Clostridium putrefaciens.

[0057] In the present invention, the recombinant protein of Clostridium putrefaciens alpha toxin is purified by nickel column affinity chromatography, and the purified recombinant protein of Clostridium putrefaciens alpha toxin is used as an antigen. The first immunization is preferably emulsified with Freund's incomplete adjuvant at a ratio of 1:1 at an amount of 80-120 μg / mouse, and multiple back subcutaneous injections are performed. In the present invention, the mouse is preferably a 4-6 week old female BALB / c mouse. In the present invention, the immunization dose is further preferably 100 μg / mouse.

[0058] In the present invention, it is preferred to perform a booster immunization after two weeks, a second booster immunization in the fourth week, and blood sampling to determine the antibody titer 10 days after the second booster immunization. In the present invention, the booster immunization is preferably emulsified with Freund's complete adjuvant at a ratio of 1:1 at an amount of 80-120 μg / mouse, and multiple back subcutaneous injections are performed. In the present invention, the dose of the booster immunization is further preferably 100 μg / mouse. In the present invention, ELISA is preferably used to detect serum titer. In the present invention, the titer of the polyclonal antibody to Clostridium putrefaciens alpha toxin is 1:1024×10 3 In the present invention, conventional purification methods can be selected according to actual needs to obtain Clostridium putrefaciens alpha toxin protein mouse polyclonal antibodies. In the present invention, Protein A purification method is preferably used to obtain Clostridium putrefaciens alpha toxin protein mouse polyclonal antibodies with higher titers.

[0059] The invention provides an application of the polyclonal antibody of Clostridium putrefaciens alpha toxin in preparing a test strip for detecting sheep rapid disease.

[0060] The invention provides a colloidal gold test strip for detecting sheep rapid disease. The test strip comprises a PVC plate, on which a sample pad, a gold label binding pad, a chromatographic membrane and a water absorbent pad are overlapped in sequence, the gold label binding pad is coated with the polyclonal antibody of Clostridium putrefaciens alpha toxin marked by colloidal gold particles, or the polyclonal antibody of Clostridium putrefaciens alpha toxin obtained by the preparation method and marked by colloidal gold particles; a detection line and a quality inspection line are sequentially arranged on the chromatographic membrane, the detection line is coated with the polyclonal antibody of Clostridium putrefaciens alpha toxin or the polyclonal antibody of Clostridium putrefaciens alpha toxin obtained by the preparation method, and the quality inspection line is coated with sheep anti-mouse IgG antibody.

[0061] In the present invention, the sample pad is provided with a spotting hole.

[0062] In the present invention, the chromatography membrane is preferably a nitrocellulose membrane (Sartorius CN 90 / 140).

[0063] In the present invention, the sheep blight is caused by Clostridium putrefaciens, and more preferably, is caused by alpha toxin of Clostridium putrefaciens.

[0064] In the present invention, the concentration of the Clostridium putrefaciens alpha toxin polyclonal antibody is preferably 0.5-3.0 mg / mL, more preferably 1.0-2.0 mg / mL; the concentration of the goat anti-mouse IgG antibody is preferably 1.0-4.0 mg / mL, more preferably 2.0-3.0 mg / mL.

[0065] In the present invention, the method for preparing the colloidal gold test strip preferably comprises the following steps: preparing a colloidal gold-antibody conjugate stock solution, diluting the colloidal gold-antibody conjugate stock solution and applying it on a glass fiber membrane to obtain a gold-labeled conjugate pad;

[0066] The polyclonal antibody against alpha toxin of Clostridium putrefaciens and the goat anti-mouse IgG antibody are diluted respectively and then spotted on the chromatographic membrane to form a chromatographic membrane containing a detection line and a quality control line;

[0067] The colloidal gold test strip is prepared by sequentially attaching a fixed sample pad, a gold label binding pad, a chromatography membrane and a water absorbent pad on a PVC bottom plate. The schematic diagram of the test strip structure is shown in Figure 1 .

[0068] In the present invention, the preparation method of the colloidal gold solution can be prepared by conventional preparation methods well known in the art according to actual needs. In the present invention, the colloidal gold solution is preferably prepared by a trisodium citrate reduction method, and the specific steps are preferably as follows: 0.01% chloroauric acid solution is heated to a boil, and then 1% trisodium citrate solution is added to prepare colloidal gold, and after cooling to room temperature, the colloidal gold solution is restored to its original volume with purified water to obtain a colloidal gold solution.

[0069] In the present invention, the method for preparing the colloidal gold-antibody conjugate stock solution preferably comprises the following steps:

[0070] Take 20mL of colloidal gold solution, add 450μL of 0.2M K2CO3 to adjust the pH, then add 2mL of 1mg / mL Clostridium putrefaciens α-toxin polyclonal antibody solution, stir at room temperature for 30min, and add 10% BSA to a final concentration of 1%, and continue stirring for 30min. Then centrifuge the colloidal gold solution at 4℃ and 12000r / min for 10min, discard the supernatant, add 2mL of colloidal gold re-solution to the precipitate and resuspend it, and the colloidal gold-antibody conjugate stock solution is stored at 4℃ in the dark.

[0071] The method for determining the result of the colloidal gold test strip of the present invention is as follows: take 100 μL of the sample to be tested, drop it into the sample spotting hole of the colloidal gold test strip, react at room temperature for 10-15 minutes, and observe the result. If only one rose red line appears on the C line, it is negative; if two rose red lines appear on the T line and the C line, it is positive; if there is no red line, the test strip is invalid.

[0072] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0073] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0074] Example 1 Recombinant construction and expression and purification of Clostridium putrefaciens alpha toxin protein

[0075] 1. Extraction of the Whole Genome of Clostridium putrefaciens

[0076] The whole genome of Clostridium putrefaciens was extracted according to the instructions of the whole genome extraction kit.

[0077] 2. Amplification of the α-toxin gene of Clostridium putrefaciens

[0078] The full length of the α-toxin gene of Clostridium putrefaciens was 1323 bp. Primer 5.0 was used to design primers for the α-toxin gene of Clostridium putrefaciens. The primers are shown below, and the restriction sites are marked with black lines. The primers were sent to Xi'an Qingke Company for synthesis.

[0079] Upstream primer 5'-ccg gaattc ATGTCAAAAAAATCTTTTGCTAAAA-3'(SEQ ID NO.2); downstream primer 5'-ccg ctcgag ATTAATATCAATTTTTTTATCATTG-3' (SEQ ID NO. 3).

[0080] The total volume of the PCR reaction system was 50 μL, including 25 μL of 2× Pro Taq HS Probe Premix, 2 μL of upstream and downstream primers, 2 μL of template, and RNA-free water was added to 50 μL.

[0081] The reaction conditions were: 98°C, 2 min; 98°C, 10 s, 55°C, 5 s, 72°C, 10 s, 35 cycles; 72°C, 10 min.

[0082] The results of the whole genome extraction of Clostridium putrefaciens are as follows Figure 2 As shown, the complete genome of Clostridium putrefaciens can be obtained. The PCR amplification results of the α-toxin gene of Clostridium putrefaciens are shown in Figure 3 As shown, a target band of about 1323 bp can be seen. The above results indicate that the α-toxin gene fragment of Clostridium putrefaciens was successfully obtained and named α-1323.

[0083] 3. Recombinant Construction of Clostridium putrefaciens α-toxin Protein

[0084] Extract the pET-30a plasmid according to the instructions of the plasmid extraction kit. Then use EcoR I and Xho I to digest the α toxin gene and the PET-30a plasmid, identify the nucleic acid by electrophoresis and recover the gel. The recovered product was connected with T4 quick ligase at 16°C for 30 minutes and then transferred into DH5α competent cells for overnight culture. Pick the monoclonal colony for PCR and enzyme digestion identification. The successfully identified recombinant plasmid was transferred into BL21 expression competent cells for expression.

[0085] like Figure 4The results showed that after double enzyme digestion, a 1323bp gene fragment of Clostridium putrefaciens α-toxin was generated, indicating that the pET-30a-Clostridium putrefaciens α-toxin recombinant plasmid was successfully constructed and named pET-30a-α1323.

[0086] 4. Expression and purification of Clostridium putrefaciens α-toxin protein

[0087] Small-scale induction found that the expression of Clostridium putrefaciens α-toxin protein was the highest at 37°C and 180 rpm / min, and large-scale expression could be performed under this condition. The specific process is as follows: After the recombinant bacterial solution was revived overnight, it was added to 200 ml LB medium at a ratio of 1:100 and shaken to the logarithmic phase (OD 600 =0.6-0.8), IPTG was added at a final concentration of 0.2 mM for overnight induction, and the mixture was centrifuged at 8000 rpm for 20 min, and the supernatant was discarded. The bacterial pellet was resuspended in about 20 ml of PBS, and the cell was disrupted by ultrasonication for 40 min, and then centrifuged at 8000 rpm for 20 min, and the supernatant and pellet were collected and identified by SDS-PAGE electrophoresis.

[0088] like Figure 5 The results show that after IPTG induction, the target protein of about 48 kDa can be seen, and the protein is expressed in the supernatant ( Figure 5 A). The protein was further purified by nickel column affinity chromatography, such as Figure 5 Result B shows: After purification, a single band of Clostridium putrefaciens alpha toxin protein was obtained.

[0089] Example 2 Preparation of polyclonal antibodies to alpha toxin protein of Clostridium putrefaciens

[0090] Twenty female BALB / c mice aged 4 to 6 weeks were selected, and the purified recombinant protein of Clostridium putrefaciens α-toxin obtained in Example 1 was used as an antigen, and the mice were immunized by multiple back subcutaneous injections at a dose of 100 μg / mouse; two weeks later, a booster immunization of 100 μg / mouse was performed, and a second booster immunization was performed in the fourth week. Blood was collected 10 days after the second booster immunization to determine the antibody titer, and mouse serum was collected and purified using Protein A to obtain mouse polyclonal antibodies to Clostridium putrefaciens α-toxin protein. The results are shown in Figure 2. Figure 6 As shown: The mouse polyclonal antibody against α-toxin protein of Clostridium putrefaciens can specifically bind to the antigen, and the titer of the polyclonal antibody is 1:1024×10 3 This indicates that the experiment of the present invention successfully prepared a mouse polyclonal antibody against the α-toxin protein of Clostridium putrefaciens with a relatively high titer.

[0091] Example 3 Preparation of sheep rapid disease colloidal gold test strips

[0092] (1) Preparation of colloidal gold solution: colloidal gold solution was prepared by trisodium citrate reduction method. 0.01% chloroauric acid solution was heated to a boil and then 1% trisodium citrate solution was added to prepare colloidal gold. After cooling to room temperature, the solution was restored to its original volume with purified water.

[0093] (2) Preparation of colloidal gold-antibody conjugate stock solution: Take 20 mL of colloidal gold solution, add 450 μL of 0.2M K2CO3 to adjust the pH to 7.0, then add 2 mL of 1 mg / mL Clostridium putrefaciens α-toxin polyclonal antibody solution, stir at room temperature for 30 min, and add 10% BSA to a final concentration of 1%, and continue stirring for 30 min. Then centrifuge the colloidal gold solution at 4°C and 12000 r / min for 30 min, discard the supernatant, add 2 mL of colloidal gold re-solution to the precipitate and resuspend it to obtain the colloidal gold-antibody conjugate stock solution, which is stored at 4°C in the dark.

[0094] The prepared colloidal gold-antibody conjugate stock solution is sprayed on the surface of the glass fiber membrane to obtain a gold-labeled conjugate pad.

[0095] (3) Determination of the test line and quality control line: The polyclonal antibody against α-toxin of Clostridium putrefaciens was diluted to 1.0 mg / mL with diluent to coat the test line, and the goat anti-mouse IgG was diluted to 1.5 mg / mL with diluent to coat the control line, thereby forming a chromatographic membrane containing the test line and quality control line.

[0096] (4) Assembling the test strip: The sample pad, the gold label binding pad, the chromatography membrane and the water absorption pad are overlapped and fixed on the PVC bottom plate in sequence to prepare the colloidal gold test strip.

[0097] Example 4 Specificity determination of sheep fast disease colloidal gold test strip

[0098] Using the positive serum of Clostridium putrefaciens, Escherichia coli, Salmonella, Pasteurella and Staphylococcus aureus preserved in the Key Laboratory of Animal Disease Pathogen Diagnosis and Green Control Technology Research in Qinghai Province, 100 μL of each was added dropwise to the colloidal gold test strip sample well prepared in Example 3, reacted at room temperature for 10 minutes, and the results were observed. If only one rose-red line appears on the C line, it is negative; if two rose-red lines appear on the T line and the C line, it is positive; if there are no red lines, the test strip is invalid. Figure 7 The results showed that the test strip could react specifically with Clostridium putrefaciens serum samples, indicating that the test strip had good specificity.

[0099] Example 5 Sensitivity determination of sheep rapid disease colloidal gold test strip

[0100] Use PBS to dilute Clostridium putrefaciens positive serum by 2.5 times, 5 times, 10 times, 20 times, 40 times, and 80 times, respectively, and add about 150 μL to the sample wells, react at room temperature for 10-15 minutes, and observe the results. If only one rose red line appears on the C line, it is negative; if two rose red lines appear on the T line and the C line, it is positive; if there is no red line on both lines, the test strip is invalid. Figure 8 The results showed that the test strip still reacted when the Clostridium putrefaciens serum sample was diluted 40 times, indicating that the test strip had good sensitivity.

[0101] Example 6 Clinical sample detection

[0102] The 33 sheep serum samples collected in Yushu, Qinghai were tested using the colloidal gold test strips prepared in Example 3 of the present invention and ELISA test (clostridium perfringens toxin antibody detection kit-sheep fast disease, kernel, USA, purchased from Guangzhou Cedi Biotechnology Co., Ltd.). Fig. 9 The results showed that the two methods detected 18 positive samples (5 of which were positive results as shown in Fig.10 As shown in the figure, the total number of negative samples detected was 12, and the other 3 samples were suspicious. Therefore, the positive conformity rate of the test strip was 100%, and the negative conformity rate of the test strip was 80%. At the same time, the results of the two tests were consistent with 30 samples, so the conformity rate of the test strip prepared by the invention was 90.9%, indicating that the test strip had good accuracy.

[0103] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A polyclonal antibody against alpha toxin of Clostridium putrefaciens, characterized in that: The polyclonal antibody to the alpha toxin of Clostridium putrefaciens is prepared by immunizing test animals with an antigen of the alpha toxin of Clostridium putrefaciens. The amino acid sequence of the alpha toxin antigen of Clostridium putrefaciens is shown in SEQ ID NO.

1.

2. The polyclonal antibody against alpha toxin of Clostridium putrefaciens according to claim 1, characterized in that: The method for preparing the alpha toxin antigen of Clostridium putrefaciens comprises the following steps: The whole genome of Clostridium putrefaciens was extracted, and the alpha toxin gene of Clostridium putrefaciens was amplified using the alpha toxin gene primers of Clostridium putrefaciens; Connecting the Clostridium putrefaciens alpha toxin gene to a vector to obtain a recombinant vector; The recombinant protein of alpha toxin of Clostridium putrefaciens is obtained by in vitro recombinant expression and purification, and the recombinant protein of alpha toxin of Clostridium putrefaciens is used as the alpha toxin antigen of Clostridium putrefaciens.

3. The polyclonal antibody against alpha toxin of Clostridium putrefaciens according to claim 2, characterized in that: The primers include an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is shown as SEQ ID NO.2; the nucleotide sequence of the downstream primer is shown as SEQ ID NO.

3.

4. The polyclonal antibody against alpha toxin of Clostridium putrefaciens according to claim 2, characterized in that: The vector is pET-30a.

5. The method for preparing the polyclonal antibody against alpha toxin of Clostridium putrefaciens according to any one of claims 1 to 4, characterized in that: The steps include: The purified recombinant protein of alpha toxin of Clostridium putrefaciens was used as an antigen to immunize mice subcutaneously at multiple points on the back; a booster immunization was performed two weeks later, and a second booster immunization was performed in the fourth week; After the second booster immunization, blood was collected to determine the antibody titer, mouse serum was collected, and protein A was used to purify the mouse polyclonal antibody against the alpha toxin protein of Clostridium putrefaciens.

6. The preparation method according to claim 5, characterized in that: The immunization dose is 80-120 μg / mouse.

7. Use of the polyclonal antibody against alpha toxin of Clostridium putrefaciens according to any one of claims 1 to 4 in the preparation of a test strip for detecting sheep rapid disease.

8. A colloidal gold test strip for detecting sheep rapid disease, the test strip comprising a PVC plate, on which a sample pad, a gold label binding pad, a chromatographic membrane and a water absorbent pad are sequentially overlapped, characterized in that: The gold-labeled binding pad is coated with the polyclonal antibody to the alpha toxin of Clostridium putrefaciens according to any one of claims 1-4 labeled with colloidal gold particles, or the polyclonal antibody to the alpha toxin of Clostridium putrefaciens obtained by the preparation method according to any one of claims 5-6 labeled with colloidal gold particles; a detection line and a quality inspection line are sequentially arranged on the chromatographic membrane, the detection line is coated with the polyclonal antibody to the alpha toxin of Clostridium putrefaciens according to any one of claims 1-4, or the polyclonal antibody to the alpha toxin of Clostridium putrefaciens obtained by the preparation method according to any one of claims 5-6, and the quality inspection line is coated with sheep anti-mouse IgG antibody.

9. The colloidal gold test strip according to claim 8, characterized in that: The sheep blight is caused by Clostridium putrefaciens.

10. The colloidal gold test strip according to claim 8, characterized in that: The concentration of the polyclonal antibody to alpha toxin of Clostridium putrefaciens is 0.5-3.0 mg / mL; the concentration of the goat anti-mouse IgG antibody is 1.0-4.0 mg / mL.

Citation Information

Patent Citations

  • Clostridium septicum alpha toxin mutant, gene thereby, preparation method and clostridium septicum vaccine

    CN109111509A

  • Colloidal gold test strip for detecting clostridium septicum and preparation method and application thereof

    CN111948388A

Cited By

  • Monoclonal antibody specifically combined with clostridium septicum alpha toxin recombinant protein, hybridoma cell strain and application

    CN120082520A

  • Monoclonal antibody specifically binding to clostridium perfringens alpha toxin recombinant protein, hybridoma cell strain and application thereof

    CN120082520B